Dabrafenib and trametinib–induced hyperglycemia with decreased insulin secretion in a patient with lung adenocarcinoma
Kohei Nagano, Masaki Suzuki, Saki Morikawa, Rikiya Watanabe, Takeshi Ohara, Kenta Hara · 2026
Read Dabrafenib and trametinib–induced hyperglycemia with decreased insulin secretion in a patient with lung adenocarcinoma by Kohei Nagano, Masaki Suzuki, Saki Morikawa, Rikiya Watanabe, Takeshi Ohara, Kenta Hara (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13538961.txt.
Description
Six doctors in Japan describe an eighty-year-old man whose blood sugar soared on a pair of targeted cancer drugs, in a case report published in 2026. The man had lung cancer carrying a gene change that the drugs dabrafenib and trametinib attack. Before treatment he was obese and had mild diabetes he did not know about. Seven months into therapy, his blood sugar spiked and his body made far less insulin.
Tests that track insulin output showed a telling pattern with the drugs. When the pair was paused, his insulin making recovered; when it restarted, the output faded again step by step. That on-off pattern pins the harm on the treatment rather than on his prior diabetes alone. The authors urge doctors to watch both blood sugar and insulin output in patients on this drug pair. Catching the slide early can guide dose changes before harm deepens.
Catalog record
| CREATOR | Kohei Nagano, Masaki Suzuki, Saki Morikawa, Rikiya Watanabe, Takeshi Ohara, Kenta Hara |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |